Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in
patients with metastatic colorectal cancer (mCRC) who are receiving second-line
irinotecan-based chemotherapy concomitantly with panitumumab.